Rivaroxaban for thromboprophylaxis in high-risk cancer patients: CASSINI results

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with cancerПодробнее

Alok Khorana: Rivaroxaban Prevents Cancer-Associated VTEПодробнее

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapyПодробнее

Rivaroxaban for thromboprophylaxis in high risk ambulatory patients with cancerПодробнее

Alok Khorana, MD: Prophylactic Treatment With Rivaroxaban Reduces Cancer Patients' VTE RiskПодробнее

Rivaroxaban in Cancer-Associated VTE: Results from CALLISTOПодробнее

Alok A. Khorana: Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer PatientsПодробнее

Cancer-Associated Thrombosis and Antiphospholipid Syndrome: An Update for CliniciansПодробнее

CASSINI: can we prevent thrombosis in cancer patients who are at risk?Подробнее

Rivaroxaban in Cancer Does It Really Prevent Blood ClotsПодробнее

Updated ASCO guidelines for VTE in cancerПодробнее

How is cancer-related venous thromboembolism treated in real world practice?Подробнее

Prediction and Prevention of Cancer-Associated Thromboembolism (CAT)Подробнее

Quality assessment looking at rivaroxaban for cancer-related thrombosisПодробнее

RPTH Recap: Thromboprophylaxis w/ rivaroxaban in patients w/ malignancy & central venous linesПодробнее

Bleeding, Gastrointestinal Cancer, & Apixaban, Rivaroxaban, or Enoxaparin for Acute VTEПодробнее

Rivaroxaban for Thromboprophylaxis in High Risk Ambulatory Patients with CancerПодробнее

Oral Anticoagulants in Cancer Patients: Mixed-Results and a Lesson about Trial EnrichmentПодробнее

Following Thromboprophylaxis Guidelines in Cancer Patients-the Real WorldПодробнее